Asure Software (ASUR) Prices 2.6M Share Common Offering at $7.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
After-Hours Stock Movers 12/17: (MREO) (DMTK) (BW) Higher; (SCHL) (SCS) (ASUR) Lower (more...)
December 17, 2020 5:37 PM ESTToday's After-Hours Stock Movers:
Mereo BioPharma Group plc (NASDAQ: MREO) 30.3% HIGHER; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Mereo BioPharma Group plc (NASDAQ: MREO) today announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI). Setrusumab is an investigational anti-sclerostin fully human monoclonal antibody that has shown... More
Asure Software (ASUR) to Offer Common Stock
December 17, 2020 4:01 PM ESTAsure Software, Inc. (NASDAQ: ASUR) announced that it intends to offer and sell newly issued shares of its common stock in an underwritten public offering. Asure is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of... More
